#News: Editas Medicine announces Chief Financial Officer transition. Read the press release for details: https://bit.ly/4hltkM4 #invivogeneediting #geneediting #biotechnology
Editas Medicine
生物技术研究
Cambridge，Massachusetts 47,995 位关注者
What If You Could Repair Broken Genes?
关于我们
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
- 网站
-
https://www.editasmedicine.com
Editas Medicine的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2013
- 领域
- Genome Editing、In Vivo (in body) Editing、Engineered Cell Medicines、Ocular Medicines、Genetic Diseases、Blood Diseases、Sickle Cell Disease、Cancer、Rare Diseases、Immunogenetics、Transfusion-Dependent Beta Thalassemia和Hematopoietic Stem Cells
地点
Editas Medicine员工
动态
-
This week our CEO Gilmore ONeill and CFO Erick Lucera participated in the Leerink Partners Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference where we shared our perspective on innovation in the field of gene editing. #invivogeneediting #geneediting #biotechnology
-
-
On this Employee Appreciation Day, we thank our employees (Editors) for all they do. Driven by a shared purpose and passion to develop medicines for people living with serious diseases. Thank you for your collaboration, innovation, and amazing fortitude. #EmployeeAppreciationDay #InsideEditas?
-
-
Yesterday, we reported fourth quarter and full year 2024 financial results and business updates. Learn more: https://bit.ly/4hWK79n #invivogeneediting #geneediting #biotechnology?
-
Today, we announced fourth quarter and full year 2024 financial results and business updates. Read the press release for details: https://bit.ly/4hWK79n #invivogeneediting #geneediting #biotechnology?
-
-
Today our CEO Gilmore ONeill and CFO Erick Lucera are speaking about innovation in the field of in vivo gene editing at the TD Cowen 45th Annual Health Care Conference. #biotechnology #geneediting #invivogeneediting
-
-
In recognition of #RareDiseaseDay, Editors share their thoughts on the importance of this day. #rarediseases #geneediting #biotechnology #InsideEditas?
-
Today is #RareDiseaseDay, and our Editors are showing their stripes in support of those impacted by rare diseases. Learn more about #RareDiseases and how you can get involved by visiting: https://lnkd.in/e2nh5pd or https://lnkd.in/gk6hbAF #ShowYourStripes #InsideEditas?
-
February 28 is #RareDiseaseDay, and we will be joining the #raredisease community in raising awareness and generating change for those impacted by #rarediseases and their loved ones. To learn more, visit: https://lnkd.in/e2nh5pd and https://lnkd.in/gk6hbAF #showyourstripes?
-
-
#News: Editas Medicine to announce fourth quarter/full year 2024 financial results and to participate in investor conferences in March. Read the press release for details: https://bit.ly/41g7W4G #geneediting #invivogeneediting #biotechnology
-